المؤلفون: K. D. Popov, T. M. Alekseeva, V. D. Nazarov, A. I. Vlasenko, S. M. Malyshev, К. Д. Попов, Т. М. Алексеева, В. Д. Назаров, А. И. Власенко, С. М. Малышев

المساهمون: Funds of the Ministry of Health of Russia., Средства Министерства здравоохранения Российской Федерации.

المصدر: Neuromuscular Diseases; Том 13, № 3 (2023); 33-39 ; Нервно-мышечные болезни; Том 13, № 3 (2023); 33-39 ; 2413-0443 ; 2222-8721 ; 10.17650/2222-8721-2023-13-3

مصطلحات موضوعية: тау-белок, markers of treatment response, nusinersen, neurofilaments, tau-protein, маркеры ответа на терапию, нусинерсен, нейрофиламенты

وصف الملف: application/pdf

Relation: https://nmb.abvpress.ru/jour/article/view/557/357; Butchbach M.E.R. Genomic variability in the survival motor neuron genes (SMN1 and SMN2): Implications for spinal muscular atrophy phenotype and therapeutics development. Int J Mol Sci 2021;22(15):7896. DOI:10.3390/ijms22157896; Kariyawasam D.S.T., D’Silva A., Lin C. et al. Biomarkers and the development of a personalized medicine approach in spinal muscular atrophy. Front Neurol. 2019;10:898. PMID: 31481927. DOI:10.3389/fneur.2019.00898; Calucho M., Bernal S., Alías L. et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord 2018;28(3):208–15. DOI:10.1016/j.nmd.2018.01.003; Yuan A., Rao M.V., Veeranna Nixon R.A. Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol 2017;9(4):a018309. DOI:10.1101/cshperspect.a018309; Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233(1– 2):183–98. DOI:10.1016/j.jns.2005.03.015; Darras B.T., Crawford T.O., Finkel R.S. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol 2019;6(5):932–44. DOI:10.1002/acn3.779; Muntoni R., Sumner C., Darras B. et al. Association between plasma phosphorylated neurofilament heavy chain and efficacy endpoints in the nusinersen NURTURE Study. Neuromuscul Disord 2019;29(S1):S146. DOI:10.1016/j.nmd.2019.06.384; Nitz E., Smitka M., Schallner J. et al. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. Ann Clin Transl Neurol 2021;8(10):2013–24. DOI:10.1002/acn3.51449; Olsson B., Alberg L., Cullen N. C. et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J Neurol 2019;266(9):2129–36. DOI:10.1007/s00415-019-09389-8; Johannsen J., Weiss D., Daubmann A. et al. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen. J Cell Mol Med 2021;25(17):8419–31. DOI:10.1111/jcmm.16802; Verma S., Perry K., Razdan R. et al. CSF IL-8 Associated with response to gene therapy in a case series of spinal muscular atrophy. Neurotherapeutics 2023;20(1):245–53. DOI:10.1007/s13311-022-01305-9; Wurster C.D., Günther R., Steinacker P. et al. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Ther Adv Neurol Disord 2019;12:1756286419846058. DOI:10.1177/1756286419846058; Freigang M., Steinacker P., Wurster C.D. et al. Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy. Ann Clin Transl Neurol 2022;9(9):1437–48. DOI:10.1002/acn3.51645; Milella G., Introna A., D’Errico E. et al. Cerebrospinal fluid and clinical profiles in adult type 2–3 spinal muscular atrophy patients treated with nusinersen: An 18-month single-centre experience. Clin Drug Investig 2021;41(9):775–84. DOI:10.1007/s40261-021-01071-0; Faravelli I., Meneri M., Saccomano D. et al. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients. J Cell Mol Med 2020;24(5):3034–9. DOI:10.1111/jcmm.14939; De Wel B., de Schaepdryver M., Poesen K., Claeys K.G. Biochemical and clinical biomarkers in adult SMA 3–4 patients treated with nusinersen for 22 months. Ann Clin Transl Neurol 2022;9(8):1241–51. DOI:10.1002/acn3.51625; Šimić G., Vukić V., Babić M. et al. Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen. CNS Neurosci Ther 2022. DOI:10.1111/cns.14051; Paris A., Bora P., Parolo S. et al. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen. CPT Pharmacometrics Syst Pharmacol 2023;12(2):196–206. DOI:10.1002/psp4.12890; Walter M. C., Wenninger S., Thiele S. et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3: A prospective observational study. J Neuromuscul Dis 2019;6(4):453–65. DOI:10.3233/JND-190416; Hromadkova L., Siddiqi M.K., Liu H., Safar J. G. Populations of tau conformers drive prion-like strain effects in Alzheimer’s disease and related dementias. Cells 2022;11(19):2997. DOI:10.3390/cells11192997; Blennow K., Hampel H., Weiner M., Zettenberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6(3):131–44. DOI:10.1038/nrneurol.2010.4; Totzeck A., Stolte B., Kizina K. et al. Neurofilament heavy chain and tau protein are not elevated in cerebrospinal fluid of adult patients with spinal muscular atrophy during loading with nusinersen. Int J Mol Sci 2019;20(21):5397. DOI:10.3390/ijms20215397; Wyss M., Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev 2000;80(3):1107–213. DOI:10.1152/physrev.2000.80.3.1107; Alves C.R.R., Zhang R., Johnstone A.J. et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy Neurology 2020;94(9):e921–e931. DOI:10.1212/WNL.0000000000008762; Freigang M., Wurster C.D., Hagenacker T. et al. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment. Ann Clin Transl Neurol 2021;8(5):1049–63. DOI:10.1002/acn3.51340; Abati E., Citterio G., Bresolin N. et al. Glial cells involvement in spinal muscular atrophy: Could SMA be a neuroinflammatory disease? Neurobiol Dis 2020;140:104870. DOI:10.1016/j.nbd.2020.104870; Freigang M., Steinacker P., Wurster C. D. et al. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet J Rare Dis 2021;16(1):330. DOI:10.1186/s13023-021-01961-8; Kobayashi Y., Ishikawa N., Tateishi Y. et al. Evaluation of cerebrospinal fluid biomarkers in pediatric patients with spinal muscular atrophy. Brain Dev 2023;45(1):2–7. DOI:10.1016/j.braindev.2022.09.008; Stolte B., Nonnemacher M., Kizina K. et al. Nusinersen treatment in adult patients with spinal muscular atrophy: A safety analysis of laboratory parameters. J Neurol 2021;268(12):4667–79. DOI:10.1007/s00415-021-10569-8; Orbach R., Sagi L., Sadot E. et al. Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy. Muscle Nerve 2022;66(6):762–6. DOI:10.1002/mus.27731; Kessler T., Latzer P., Schmid P. et al. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J Neurochem 2020;153(5):650–61. DOI:10.1111/jnc.14953; Gingele S., Hümmert M. W., Alvermann S. et al. Routine cerebrospinal fluid cytology reveals unique inclusions in macrophages during treatment with nusinersen. Front Neurol 2019;10:735. DOI:10.3389/fneur.2019.00735; Schafernak K.T., Jacobsen J.R., Hernandez D. et al. Cytochemical characterization of cerebrospinal fluid macrophage inclusions in pediatric patients receiving intrathecal nusinersen (SPINRAZA®) for spinal muscular atrophy. Acta Cytol 2022;66(1):79–84. DOI:10.1159/000518005; Magri F., Vanoli F., Corti S. miRNA in spinal muscular atrophy pathogenesis and therapy. J Cell Mol Med 2018;22(2):755–67. DOI:10.1111/jcmm.13450; Bonanno S., Marcuzzo S., Malacarne C. et al. Circulating myomiRs as potential biomarkers to monitor response to nusinersen in pediatric SMA patients. Biomedicines 2020;8(2):21. DOI:10.3390/biomedicines8020021; Magen I., Aharoni S., Yacovzada N. S. et al. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients. Eur J Neurol 2022;29(8):2420–30. DOI:10.1111/ene.15382; Zaharieva I.T., Scoto M., Aragon-Gawinska K. et al. Response of plasma microRNAs to nusinersen treatment in patients with SMA. Ann Clin Transl Neurol 2022;9(7):1011–26. DOI:10.1002/acn3.51579; Geyer P.E., Holdt L.M., Teupser D., Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 2017;13(9):942. DOI:10.15252/msb.20156297; Schorling D.C., Kölbel H., Hentschel A. et al. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol 2022;29(7):2084–96. DOI:10.1111/ene.15331; Introna A., Milella G., D’Errico E. et al. Is cerebrospinal fluid amyloid-β42 a promising biomarker of response to nusinersen in adult spinal muscular atrophy patients? Muscle Nerve 2021;63(6):905–9. DOI:10.1002/mus.27212; Wadman R.I., Stam M., Jansen M.D. et al. A comparative study of SMN protein and mRNA in blood and fibroblasts in patients with spinal muscular atrophy and healthy controls. PLoS One 2016;11(11):e0167087. DOI:10.1371/journal.pone.0167087; Otsuki N., Arakawa R., Kaneko K. et al. A new biomarker candidate for spinal muscular atrophy: identification of a peripheral blood cell population capable of monitoring the level of survival motor neuron protein. PLoS One 2018;13(8):e0201764. DOI:10.1371/journal.pone.0201764; Czech C., Tang W., Bugawan T. et al. Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls. PLoS One 2015;10(10):e0139950. DOI:10.1371/journal.pone.0139950; https://nmb.abvpress.ru/jour/article/view/557

الاتاحة: https://nmb.abvpress.ru/jour/article/view/557
https://doi.org/10.17650/2222-8721-2023-13-3-33-39

المؤلفون: Louis S. Matza, Donald L. Patrick, Anne W. Riley, John J. Alexander, Luis Rajmil, Andreas M. Pleil, Monika Bullinger, Р. А. Гапешин, С. М. Малышев, А. С. Колбин

المصدر: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 2 (2015); 44-69 ; Качественная клиническая практика; № 2 (2015); 44-69 ; 2618-8473 ; 2588-0519

مصطلحات موضوعية: task force, дети, ISPOR, маркировка медицинского продукта, сообщаемые пациентами исходы, педиатрия, PRO, исследовательская группа, adolescents, children, medical product labeling, patient-reported outcomes, pediatrics

وصف الملف: application/pdf

Relation: https://www.clinvest.ru/jour/article/view/16/16; Food and Drug Administration. Guidance for Industry - Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. SilverSpring, MD: Food and Drug Administration, 2009.; Patrick D.L., Burke L.B., Powers J.H., et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007;10 (Suppl. 2):S125-37.; Burke L.B., Kennedy D.L., Miskala P.H., et al. The use of patient-reported outcome measures in the evaluation of medical products for regulatory approval. Clin Pharmacol Ther 2008;84:281-3.; Gnanasakthy A., Mordin M., Clark M., et al. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 2012;15:437-42.; European Medicines Agency. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. London, United Kingdom: European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP), 2005.; Connolly M.A., Johnson J.A. Measuring quality of life in paediatric patients. Pharmacoeconomics 1999;16:605-25.; Drotar D. Measuring Health-Related Quality of Life in Children and Adolescents: Implication for Research and Practice. Mahwah, NJ: Erlbaum, 1998.; Eiser C., Mohay H., Morse R. The measurement of quality of life in young children. Child Care Health Dev 2000;26:401-14.; Eiser C., Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess 2001;5:1-157.; Eiser C., Morse R. A review of measures of quality of life for children with chronic illness. Arch Dis Child 2001;84:205-11.; Erling A. Methodological considerations in the assessment of health-related quality of life in children. Acta Paediatr Suppl 1999;88:106-7.; De Civita M., Regier D., Alamgir A.H., et al. Evaluating health-related quality-of-life studies in paediatric populations: some conceptual, methodological and developmental considerations and recent applications. Pharmacoeconomics 2005;23:659-85.; Hinds P.S., Brandon J., Allen C., et al. Patient-reported outcomes in end-of-life research in pediatric oncology J Pediatr Psychol, 32 (2007), pp. 1079-1088; Landgraf J.M. Practical considerations in the measurement of HRQoL in child/adolescent clinical trials. P. Fayers, R. Hays (Eds.), Accessing Quality of Life in Clinical Trials (2nd ed.), Oxford University Press, New York (2005); Landgraf J.M., Abetz L.N. Measuring health outcomes in pediatric populations: issues in psychometrics and application. Qual Life Pharmacoecon Clin Trials, 2 (1996), pp. 793-802; Matza L.S., Swensen A.R., Flood E.M., et al. Assessment of health-related quality of life in children: a review of conceptual, methodological, and regulatory issues. Value Health, 7 (2004), pp. 79-92; Morris C., Gibbons E., Fitzpatrick R. Child and Parent Reported Outcome Measures: A Scoping Report Focusing on Feasibility for Routine Use in the NHS. Department of Public Health, University of Oxford, Oxford, United Kingdom (2009).; Quittner A.L., Modi A., Cruz I. Systematic review of health-related quality of life measures for children with respiratory conditions. Paediatr Respir Rev, 9 (2008), pp. 220-232; Rebok G., Riley A., Forrest C., et al. Elementary school-aged children’s reports of their health: a cognitive interviewing study. Qual Life Res, 10 (2001), pp. 59-70; Theunissen N.C., Vogels T.G., Koopman H.M., et al. The proxy problem: child report versus parent report in health-related quality of life research. Qual Life Res, 7 (1998), pp. 387-397.; Varni J.W., Limbers C.A., Burwinkle T.M. How young can children reliably and validly self-report their health-related quality of life? An analysis of 8,591 children across age subgroups with the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes, 5 (2007), p. 1.; Wallander J.L., Schmitt M., Koot H.M. Quality of life measurement in children and adolescents: issues, instruments, and applications. J Clin Psychol, 57 (2001), pp. 571-585.; Clarke S.A., Eiser C. The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes, 2 (2004), p. 66.; Cremeens J., Eiser C., Blades M. Characteristics of health-related self-report measures for children aged three to eight years: a review of the literature. Qual Life Res, 15 (2006), pp. 739-754.; Eiser C., Morse R. Can parents rate their child’s health-related quality of life? Results of a systematic review. Qual Life Res, 10 (2001), pp. 347-357.; Rajmil L., Herdman M., Fernandez de Sanmamed M.J., et al. Generic health-related quality of life instruments in children and adolescents: a qualitative analysis of content. J Adolesc Health, 34 (2004), pp. 37-45.; Ravens-Sieberer U., Erhart M., Wille N., et al. Generic health-related quality-of-life assessment in children and adolescents: methodological considerations. Pharmacoeconomics, 24 (2006), pp. 1199-1220.; Solans M., Pane S., Estrada M.D., et al. Health-related quality of life measurement in children and adolescents: a systematic review of generic and disease-specific instruments. Value Health, 11 (2008), pp. 742-764.; Bevans K.B., Riley A.W., Moon J., et al. Conceptual and methodological advances in child-reported outcomes measurement. Expert Rev Pharmacoecon Outcomes Res, 10 (2010), pp. 385-396.; Riley A.W. Evidence that school-age children can self-report on their health. Ambul Pediatr, 4 (2004), pp. 371-376.; Williams C. Gender, adolescence and the management of diabetes. J Adv Nurs, 30 (1999), pp. 1160-1166.; Patrick D.L., Edwards T.C., Skalicky A.M., et al. Validation of a quality-of-life measure for deaf or hard of hearing youth. Otolaryngol Head Neck Surg, 145 (2011), pp. 137-145.; Peden M. World report on child injury prevention appeals to “Keep Kids Safe”. Inj Prev, 14 (2008), pp. 413-414.; Office of the United Nations High Commissioner for Human Rights. Convention on the Rights of the Child. Geneva, Switzerland: United Nations, 1989.; Centers for Disease Control and Prevention. Protect the Ones You Love: Child Injuries Are Preventable. Atlanta, GA: Centers for Disease Control and Prevention, 2012.; Borse N.N., Rudd R.A., Dellinger A.M., et al. Years of Potential Life Lost Due to Unintentional Injuries among Children and Adolescents. Atlanta, GA: Centers for Disease Control and Prevention, 2012.; US Department of Health & Human Services. What Is Adolescence? Washington, D.C.: US Department of Health & Human Services, Office of Population Affairs, 2012.; Kaplan P.S. Adolescence. Houghton Mifflin Company, Boston (2004).; Grange A., Bekker H., Noyes J., et al. Adequacy of health-related quality of life measures in children under 5 years old: systematic review. J Adv Nurs, 59 (2007), pp. 197-220.; Khan F.I., Reddy R.C., Baptist A.P. Pediatric Dyspnea Scale for use in hospitalized patients with asthma. J Allergy Clin Immunol, 123 (2009), pp. 660-664.; Luby J.L., Belden A., Sullivan J., et al. Preschoolers’ contribution to their diagnosis of depression and anxiety: uses and limitations of young child self-report of symptoms. Child Psychiatry Hum Dev, 38 (2007), pp. 321-338.; Riley A., Forrest C.B., Starfield B., et al. Technical Manual for the Child Health and Illness Profile-Child Edition and CHIP-CE. The Johns Hopkins University, Baltimore, MD (2001); Ronen G.M., Streiner D.L., Rosenbaum P., et al. Health-related quality of life in children with epilepsy: development and validation of self-report and parent proxy measures. Epilepsia, 44 (2003), pp. 598-612.; Chambers C.T., Johnston C. Developmental differences in children’s use of rating scales. J Pediatr Psychol, 27 (2002), pp. 27-36.; Demetriou A., Raftopoulos A. Modeling the developing mind: from structure to change. Dev Rev, 19 (1999), pp. 319-368.; Juniper E.F., Guyatt G.H., Feeny D.H., et al. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. Eur Respir J, 10 (1997), pp. 2285-2294.; Irwin D.E., Varni J. W., Yeatts K., et al. Cognitive interviewing methodology in the development of a pediatric item bank: a Patient Reported Outcomes Measurement Information System (PROMIS) study. Health Qual Life Outcomes, 7 (2009), p. 3.; Edwards T.C., Huebner C.E., Connell F.A., et al. Adolescent quality of life, part I: conceptual and measurement model. J Adolesc, 25 (2002), pp. 275-286.; Arnett J.J. Emerging adulthood: a theory of development from the late teens through the twenties. Am Psychol, 55 (2000), pp. 469-480.; Henig R.M. What is it about 20-somethings? The New York Times. August 22 (2010) MM28.; Patrick D.L., Burke L.B., Gwaltney C.J., et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1--eliciting concepts for a new PRO instrument. Value Health, 14 (2011), pp. 967-977.; Patrick D.L., Burke L.B., Gwaltney C.J., et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health, 14 (2011), pp. 978-988.; Fehnel S. Establishing optimal requirements for content validity: a work in progress. Value Health, 12 (2009), p. 1074; Rothman M., Burke L., Erickson P., et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value Health, 12 (2009), pp. 1075-1083.; Brod M., Tesler L.E., Christensen T.L. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res, 18 (2009), pp. 1263-1278.; Leidy N.K., Vernon M. Perspectives on patient-reported outcomes: content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics, 26 (2008), pp. 363-370.; Collins D. Pretesting survey instruments: an overview of cognitive methods. Qual Life Res, 12 (2003), pp. 229-238.; Deane D.M. Content, construct, and criterion-related validity. Diabetes Educ, 17 (1991), pp. 361-362.; Gannotti M.E., Cruz C. Content and construct validity of a Spanish translation of the Pediatric Evaluation of Disability Inventory for children living in Puerto Rico. Phys Occup Ther Pediatr, 20 (2001), pp. 7-24.; McCabe M.A., Granger C.V. Content validity of a pediatric functional independence measure. Appl Nurs Res, 3 (1990), pp. 120-122.; Penny A.M., Waschbusch D.A., Klein R.M., et al. Developing a measure of sluggish cognitive tempo for children: content validity, factor structure, and reliability. Psychol Assess, 21 (2009), pp. 380-389.; Morris C., Liabo K., Wright P., et al. Development of the Oxford Ankle Foot Questionnaire: finding out how children are affected by foot and ankle problems. Child Care Health Dev, 33 (2007), pp. 559-568.; Riesch S.K., Anderson L.S., Angresano N., et al. Evaluating content validity and test-retest reliability of the children’s health risk behavior scale. Public Health Nurs, 23 (2006), pp. 366-372.; Stewart J.L., Lynn M.R., Mishel M.H. Evaluating content validity for children’s self-report instruments using children as content experts. Nurs Res, 54 (2005), pp. 414-418.; Tomlinson D., Gibson F., Treister N., et al. Understandability, content validity, and overall acceptability of the Children’s International Mucositis Evaluation Scale (ChIMES): child and parent reporting. J Pediatr Hematol Oncol, 31 (2009), pp. 416-423.; Schilling L.S., Dixon J.K., Knafl K.A., et al. Determining content validity of a self-report instrument for adolescents using a heterogeneous expert panel. Nurs Res, 56 (2007), pp. 361-366.; Harris S.R., Daniels L.E. Content validity of the Harris Infant Neuromotor Test. Phys Ther, 76 (1996), pp. 727-737.; Palisano R.J., Rosenbaum P., Bartlett D., et al. Content validity of the expanded and revised Gross Motor Function Classification System. Dev Med Child Neurol, 50 (2008), pp. 744-750.; Cox M.J., Paley B. Families as systems. Annu Rev Psychol, 48 (1997), pp. 243-267.; Pleil A.M., Kimel M., McCormack J., et al. Psychometric Assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone. Health Qual Life Outcomes, 10 (2012), p. 126.; Ungar W.J., Mirabelli C., Cousins M., et al. A qualitative analysis of a dyad approach to health-related quality of life measurement in children with asthma. Soc Sci Med, 63 (2006), pp. 2354-2366.; Ungar W.J., Boydell K., Dell S., et al. A parent-child dyad approach to the assessment of health status and health-related quality of life in children with asthma. Pharmacoeconomics, 30 (2012), pp. 697-712.; Picchietti D.L., Arbuckle R.A., Abetz L., et al. Pediatric restless legs syndrome: analysis of symptom descriptions and drawings. J Child Neurol, 26 (2011), pp. 1365-1376.; Knafl K., Deatrick J., Gallo A., et al. The analysis and interpretation of cognitive interviews for instrument development. Res Nurs Health, 30 (2007), pp. 224-234.; Varni J. W., Curtis B.H., Abetz L.N., et al. Content validity of the PedsQL 3.2 Diabetes Module in newly diagnosed patients with type 1 diabetes mellitus ages 8-45 [published online ahead of print December 27, 2012]. Qual Life Res (2012) 10.1007/s11136-012-0339-8; Chang P.C., Yeh C.H. Agreement between child self-report and parent proxy-report to evaluate quality of life in children with cancer. Psychooncology, 14 (2005), pp. 125-134.; Varni J. W., Limbers C.A., Burwinkle T.M. Parent proxy-report of their children’s health-related quality of life: an analysis of 13,878 parents’ reliability and validity across age subgroups using the PedsQL 4.0 Generic Core Scales. Health Qual Life Outcomes, 5 (2007), p. 2.; Landgraf J., Abetz L., Ware J. The CHQ User’s Manual. (2nd ed.) Health Act, Boston (1999).; Riley A.W., Forrest C.B., Starfield B., et al. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care, 42 (2004), pp. 210-220.; Varni J. W., Seid M., Kurtin P.S. Pediatric health-related quality of life measurement technology: a guide for health care decision makers. JCOM, 6 (1999), pp. 33-40.; Pickard A.S., Lin H.W., Knight S.J., et al. Proxy assessment of health-related quality of life in African American and white respondents with prostate cancer: perspective matters. Med Care, 47 (2009), pp. 176-183.; Beattie P.E., Lewis-Jones M.S. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol, 155 (2006), pp. 145-151.; Brown G.T., Wright F.V., Lang B.A., et al. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis Rheum, 53 (2005), pp. 897-904.; Brunner H.I., Klein-Gitelman M.S., Miller M.J., et al. Health of children with chronic arthritis: relationship of different measures and the quality of parent proxy reporting. Arthritis Rheum, 51 (2004), pp. 763-773.; Hutchings H.A., Upton P., Cheung W.Y., et al. Development of a parent version of the Manchester-Minneapolis quality of life survey for use by parents and carers of UK children: MMQL-UK (PF). Health Qual Life Outcomes, 6 (2008), p. 19.; Cremeens J., Eiser C., Blades M. Factors influencing agreement between child self-report and parent proxy-reports on the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales. Health Qual Life Outcomes, 4 (2006), p. 58.; Davis E., Nicolas C., Waters E., et al. Parent-proxy and child self-reported health-related quality of life: using qualitative methods to explain the discordance. Qual Life Res, 16 (2007), pp. 863-871.; De Los Reyes A., Kazdin A.E. Measuring informant discrepancies in clinical child research. Psychol Assess, 16 (2004), pp. 330-334.; Jozefiak T., Larsson B., Wichstrom L., et al. Quality of life as reported by school children and their parents: a cross-sectional survey. Health Qual Life Outcomes, 6 (2008), p. 34.; Kiss E., Kapornai K., Baji I., et al. Assessing quality of life: mother-child agreement in depressed and non-depressed Hungarian. Eur Child Adolesc Psychiatry, 18 (2009), pp. 265-273.; Vance Y.H., Morse R.C., Jenney M.E., et al. Issues in measuring quality of life in childhood cancer: measures, proxies, and parental mental health. J Child Psychol Psychiatry, 42 (2001), pp. 661-667.; Zhou H., Roberts P., Horgan L. Association between self-report pain ratings of child and parent, child and nurse and parent and nurse dyads: meta-analysis. J Adv Nurs, 63 (2008), pp. 334-342.; Upton P., Lawford J., Eiser C. Parent-child agreement across child health-related quality of life instruments: a review of the literature. Qual Life Res, 17 (2008), pp. 895-913.; Canning E.H., Hanser S.B., Shade K.A., et al. Maternal distress and discrepancy in reports of psychopathology in chronically ill children. Psychosomatics, 34 (1993), pp. 506-511.; Guyatt G.H., Juniper E.F., Griffith L.E., et al. Children and adult perceptions of childhood asthma. Pediatrics, 99 (1997), pp. 165-168.; Levi R.B., Drotar D. Health-related quality of life in childhood cancer: discrepancy in parent-child reports. Int J Cancer Suppl, 12 (1999), pp. 58-64.; Food and Drug Administration. Guidance for Industry-Acute Bacterial Otitis Media: Developing Drugs for Treatment. Food and Drug Administration, Silver Spring, MD (2012).; Janse A.J., Sinnema G., Uiterwaal C.S., et al. Quality of life in chronic illness: children, parents and paediatricians have different, but stable perceptions. Acta Paediatr, 97 (2008), pp. 1118-1124.; Klassen A.F., Miller A., Fine S. Agreement between parent and child report of quality of life in children with attention-deficit/hyperactivity disorder. Child Care Health Dev, 32 (2006), pp. 397-406.; Keller V.E., Keck J.F. An instrument for observational assessment of nausea in young children. Pediatr Nurs, 32 (2006), pp. 420-426.; Kleinman L., Rothman M., Strauss R., et al. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol, 4 (2006), pp. 588-596.; Annett R.D. Assessment of health status and quality of life outcomes for children with asthma. J Allergy Clin Immunol, 107 (Suppl.) (2001), pp. S473-S481.; Broder H.L., McGrath C., Cisneros G.J. Questionnaire development: face validity and item impact testing of the Child Oral Health Impact Profile. Community Dent Oral Epidemiol, 35 (Suppl. 1) (2007), pp. 8-19.; van Laerhoven H., van der Zaag-Loonen H.J., Derkx B.H. A comparison of Likert scale and visual analogue scales as response options in children’s questionnaires. Acta Paediatr, 93 (2004), pp. 830-835.; Christie M.J., French D., Sowden A., et al. Development of child-centered disease-specific questionnaires for living with asthma. Psychosom Med, 55 (1993), pp. 541-548.; Flesch R. A new readability yardstick. J Appl Psychol, 32 (1948), pp. 221-233.; Prout H.T., Chizik R. Readability of child and adolescent self-report measures. J Consult Clin Psychol, 56 (1988), pp. 152-154.; Likert R.A. A technique for the development of attitude scales. Educ Psychol Meas, 12 (1952), pp. 313-315.; Streiner D.L., Norman G.R. Health Measurement Scales: A Practical Guide to Their Development and Use. Oxford University Press, New York (2008).; Shields B.J., Palermo T.M., Powers J.D., et al. Predictors of a child’s ability to use a visual analogue scale. Child Care Health Dev, 29 (2003), pp. 281-290.; Herdman M., Rajmil L., Ravens-Sieberer U., et al. Expert consensus in the development of a European health-related quality of life measure for children and adolescents: a Delphi study. Acta Paediatr, 91 (2002), pp. 1385-1390.; Riley A.W., Forrest C.B., Rebok G.W., et al. The Child Report Form of the CHIP-Child Edition: reliability and validity. Med Care, 42 (2004), pp. 221-231.; Varni J.W., Seid M., Kurtin P.S. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care, 39 (2001), pp. 800-812.; Baxter S.D., Guinn C.H., Royer J.A., et al. Accuracy of children’s school-breakfast reports and school-lunch reports (in 24-h dietary recalls) differs by retention interval. Eur J Clin Nutr, 63 (2009), pp. 1394-1403.; Juniper E.F., Guyatt G.H., Feeny D.H., et al. Measuring quality of life in the parents of children with asthma. Qual Life Res, 5 (1996), pp. 27-34.; Holme S.A., Man I., Sharpe J.L., et al. The Children’s Dermatology Life Quality Index: validation of the cartoon version. Br J Dermatol, 148 (2003), pp. 285-290.; Tomlinson D., Gibson F., Treister N., et al. Refinement of the Children’s International Mucositis Evaluation Scale (ChIMES): child and parent perspectives on understandability, content validity and acceptability. Eur J Oncol Nurs, 14 (2010), pp. 29-41.; Chambers C.T., Craig K.D. An intrusive impact of anchors in children’s faces pain scales. Pain, 78 (1998), pp. 27-37.; French D.J., Christie M.J., Sowden A.J. The reproducibility of the Childhood Asthma Questionnaires: measures of quality of life for children with asthma aged 4-16 years. Qual Life Res, 3 (1994), pp. 215-224.; Valla J.P., Bergeron L., Berube H., et al. A structured pictorial questionnaire to assess DSM-III-R-based diagnoses in children (6-11 years): development, validity, and reliability. J Abnorm Child Psychol, 22 (1994), pp. 403-423.; Whitcomb S.A., Merrell K.W. Interviewing techniques. Behavioral, Social, and Emotional Assessment of Children and Adolescents (4th ed.) Routledge, New York (2013) chapter 6.; Coons S.J., Gwaltney C.J., Hays R.D., et al. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report. Value Health, 12 (2009), pp. 419-429.; Mangunkusumo R. T., Duisterhout J.S., de Graaff N., et al. Internet versus paper mode of health and health behavior questionnaires in elementary schools: asthma and fruit as examples. J Sch Health, 76 (2006), pp. 80-86.; Mussaffi H., Omer R., Prais D., et al. Computerised paediatric asthma quality of life questionnaires in routine care. Arch Dis Child, 92 (2007), pp. 678-682.; Raat H., Mangunkusumo R.T., Landgraf J.M., et al. Feasibility, reliability, and validity of adolescent health status measurement by the Child Health Questionnaire Child Form (CHQ-CF): internet administration compared with the standard paper version. Qual Life Res, 16 (2007), pp. 675-685.; Varni J.W., Limbers C.A., Burwinkle T.M., et al. The ePedsQL in type 1 and type 2 diabetes: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Internet administration. Diabetes Care, 31 (2008), pp. 672-677.; Young N.L., Varni J. W., Snider L., et al. The Internet is valid and reliable for child-report: an example using the Activities Scale for Kids (ASK) and the Pediatric Quality of Life Inventory (PedsQL). J Clin Epidemiol, 62 (2009), pp. 314-320.; Stritzke W.G., Dandy J., Durkin K., et al. Use of interactive voice response (IVR) technology in health research with children. Behav Res Methods, 37 (2005), pp. 119-126.; Bullinger M., Alonso J., Apolone G., et al. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol, 51 (1998), pp. 913-923.; Wild D., Grove A., Martin M., et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health, 8 (2005), pp. 94-104.; Guillemin F., Bombardier C., Beaton D. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J Clin Epidemiol, 46 (1993), pp. 1417-1432.; Smythe I., Everatt J., Al-Menaye N., et al. Predictors of word-level literacy amongst grade 3 children in five diverse languages. Dyslexia, 14 (2008), pp. 170-187.; Guyatt G., Walter S., Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis, 40 (1987), pp. 171-178; Leidy N.K., Revicki D.A., Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health, 2 (1999), pp. 113-127.; Revicki D., Hays R.D., Cella D., et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol, 61 (2008), pp. 102-109.; Griebsch I., Coast J., Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics, 115 (2005), pp. e600-e614.; Prosser L.A., Hammitt J.K., Keren R. Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations. Pharmacoeconomics, 25 (2007), pp. 713-726.; Ungar WJ. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?. Pharmacoeconomics, 29 (2011), pp. 641-652.; Wright D.R., Wittenberg E., Swan J.S., et al. Methods for measuring temporary health states for cost-utility analyses. Pharmacoeconomics, 27 (2009), pp. 713-723.; Kromm S.K., Bethell J., Kraglund F., et al. Characteristics and quality of pediatric cost-utility analyses. Qual Life Res, 21 (2012), pp. 1315-1325.; Ratcliffe J., Flynn T., Terlich F., et al. Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D. Pharmacoeconomics, 30 (2012), pp. 713-727.; Ravens-Sieberer U., Wille N., Badia X., et al. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Qual Life Res, 19 (2010), pp. 887-897.; Stevens K. Valuation of the Child Health Utility 9D Index. Pharmacoeconomics, 30 (2012), pp. 729-747.; Wille N., Badia X., Bonsel G., et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res, 19 (2010), pp. 875-886.; Prosser L.A. Comparative effectiveness and child health. Pharmacoeconomics, 30 (2012), pp. 637-645.; Shaddy R.E., Denne S.C. The Committee on Drugs and Committee on Pediatric Research. Clinical report-guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics, 125 (2010), pp. 850-860.; Shilling V., Williamson P.R., Hickey H., et al. Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study. Health Technol Assess, 15 (2011), pp. 1-116.; https://www.clinvest.ru/jour/article/view/16

الاتاحة: https://www.clinvest.ru/jour/article/view/16

المؤلفون: A. S. Kolbin, R. A. Gapeshin, S. M. Malyshev, А. С. Колбин, Р. А. Гапешин, С. М. Малышев

المصدر: Regulatory Research and Medicine Evaluation; № 1 (2015); 40-44 ; Регуляторные исследования и экспертиза лекарственных средств; № 1 (2015); 40-44 ; 2619-1172 ; 1991-2919 ; undefined

مصطلحات موضوعية: translational research, действенность, эффективность, трансляционные исследования, Health Technology Assessment (HTA), effectiveness, efficacy

وصف الملف: application/pdf

Relation: https://www.vedomostincesmp.ru/jour/article/view/26/10; Garrido M.V., Kristensen F.B., Nielsen C.P., et al. Оценка медицинских технологий и формирование политики здравоохранения в странах Европы. ВОЗ; 2010.; Хабриев Р.У., Ягудина Р.И., Правдюк Н.Г. Оценка технологий здравоохранения. М.: Медицинское информационное агентство; 2013.; Белоусов Ю.Б., ред. Оценка медицинских технологий. М.: ОКИ; 2013.; Kleijnen S., George E., Goulden S., et al. Relative Effectiveness Assessment of Pharmaceuticals: Similarities and Differences in 29 Jurisdictions. Value In Health 2012; (15): 954-60.; High Level Pharmaceutical Forum. Core principles on relative effectiveness. 2008.; Available from: http://www.inahta.net.; Wagner P., Srivastava S. New paradigms in translational science research in cancer biomarkers. Translational Research 2012; (4): 343-53.; Gartlehner G., Hansen R., Nissman D., et al. A simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology 2006; (10): 1040-48.; Singal A., Higgins P., Waljee A. A Primer on Effectiveness and Efficacy Trials. Clinical and Translational Gastroenterology 2014; (5): 1-4.; Marchand E., Stice E., Rohde P., et al. Moving from efficacy to effectiveness trials in prevention research. Behaviour Research and Therapy 2011; (1): 32-41.; Behnke L.M., Solis A., Shulman S.A., et al. Targeted Approach to Reducing Overutilization: Use of Percutaneous Coronary Intervention in Stable Coronary Artery Disease. Popul Health Manag. 2013; 16(3): 164-8.; Stafford R.S., Radley D.C. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003; (41): 56-61.; Hingwala J., Diamond J., Tangri N., et al. Underutilization of peritoneal dialysis: the role of the nephrologist's referral pattern. Nephrol Dial Transplant. 2013; 28(3): 732-40.; Lenfant C. Clinical Research to Clinical Practice - Lost in Translation? N Engl J Med. 2003; (349): 868-74.; Kessler R., Glasgow R.E. A proposal to speed translation of healthcare research into practice: dramatic change is needed. Am J Prev Med. 2011; 40(6): 637644.; Zwarenstein M., Treweek S., Gagnier J.J., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337: a2390.; Sox H.C. Defining comparative effectiveness research: the importance of getting it right. Med Care 2010; 48 [6 Suppl]: S7-8.; Hoagwood K., Hibbs E., Brent D., Jensen P. Introduction to the special section: efficacy and effectiveness in studies of child and adolescent psychotherapy. Journal of Consulting and Clinical Psychology 1995; (63): 683-87.; Gaglio B., Phillips S., Heurtin-Roberts S., et al. How pragmatic is it? Lessons learned using PRECIS and RE-AIM for determining pragmatic characteristics of research. Implementation Science 2014; (9): 96.; Keramaris N., Kanakaris N., Tzioupis C., et al. Translational research: From bench-side to bedside. Injury 2008; (6): 643-50.; Westfall J.M., Mold J., Fagnan L. Practice-based research - "Blue Highways" on the NIH roadmap. Journal of the American Medical Association 2007; 297(4): 403-6.; Balas E.A., Boren S.A. Yearbook of Medical Informatics. Schattauer Verlagsgesellschaft mbH. Managing Clincial Knowledge for Healthcare Improvement. Stuttgart; 2000.; Contopoulos-Ioannidis D.G., Alexiou G.A., Gouvias T.C., et al. Life cycle of translational research for medical interventions. Science 2008; 321(5894): 1298-9.; Trochim W., Kane C., Graham M.J., et al. Evaluating translational research: a process marker model. Clin Transl Sci. 2011; 4(3): 153-62.; Westfall J.M., Mold J., Fagnan L. Practice-based research - ''blue highways'' on the NIH roadmap. JAMA 2007; (297): 403-6.; Dougherty D., Conway P.H. The ''3T's'' road map to transform US health care: the ''how'' of high-quality care. JAMA 2008; (299): 2319-21.; Drolet B., Lorenzi N. Translational research: understanding the continuum from bench to bedside. Translational Research 2011; (1): 1-5.; Khoury M.J., Gwinn M., Yoon P.W., et al. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine 2007; 9(10): 665-74.; Sung N.S., Crowley W.F. Jr, Genel M., et al. Central challenges facing the national clinical research enterprise. JAMA 2003; (289): 1278-87.; Cao Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? The International Journal of Developmental Biology 2011; (55): 557-62.; Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 2009; (8): 541-46.; Wang P., Heinssen R., Oliveri M., et al. Bridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders. Neuropsychopharmacology 2009; (34): 204-12.; Schumacher A., Rujan T., Hoefkens J. A collaborative approach to develop a multiomics data analytics platform for translational research. Appl Transl Genomic. Available from: http://dx.doi.org/10.1016/j.atg.2014.09.010.; Yao Q., Lyu P., Ma F., el al. Global infometric perspective studies on translational medical research. BMC Medical informatics and Decision Making 2013; (13): 77.; Grunseth M., Chen C., Cook S., et al. Surveying the best in translation. Nature Biotechnology 2014; 32(5): 415-18.; Отчет о проведении всероссийской научной школы «Трансляционная медицина: международный опыт и тенденции развития в России». Москва. 3 ноября 2011.; Available from: http://www.almazovcentre.ru/?page_id=10962.; Kent D.M., Alsheikh-Ali A., Hayward R.A. Competing risk and heterogeneity of treatment effect in clinical trials. Trials 2008, (9): 30.; Available from: http://www.re-aim.hnfe.vt.edu/forms/reaim_framework_constructs_checklist.pdf; https://www.vedomostincesmp.ru/jour/article/view/26; undefined

الاتاحة: https://www.vedomostincesmp.ru/jour/article/view/26

المؤلفون: A. S. Kolbin, R. A. Gapeshin, S. M. Malyshev, А. С. Колбин, Р. А. Гапешин, С. М. Малышев

المصدر: Pediatric pharmacology; Том 11, № 3 (2014); 15-19 ; Педиатрическая фармакология; Том 11, № 3 (2014); 15-19 ; 2500-3089 ; 1727-5776

مصطلحات موضوعية: медицинские технологии, drugs, medical technologies, лекарственные средства

وصف الملف: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/91/83; https://www.pedpharma.ru/jour/article/view/91/84; Основные понятия в оценке медицинских технологий; метод. пособие. Под общ. ред. А. С. Колбина, С. К. Зырянова; Д. Ю. Белоусова. Москва: Издательство «ОКИ». 2013. 42 с.: ил.; Stafford R. S., Radley D. C. The underutilization of cardiac; medications of proven benefit, 1990 to 2002. J Am Coll Cardiol.; 41: 56–61.; Hingwala J., Diamond J., Tangri N. et al. Underutilization of; peritoneal dialysis: the role of the nephrologist's referral pattern.; Nephrol Dial Transplant. 2013; 28 (3): 732–40.; Lenfant C. Clinical Research to Clinical Practice — Lost in; Translation? N Engl J Med. 2003; 349: 868–874.; Kessler R., Glasgow R. E. A proposal to speed translation of; healthcare research into practice: dramatic change is needed. Am J; Prev Med. 2011; 40 (6): 637– 644.; High Level Pharmaceutical Forum. Core principles on relative; effectiveness. 2008.; Kleijnen S., George E., Goulden S. et al. Relative Effectiveness; Assessment of Phar-maceuticals: Similarities and Differences in; Jurisdictions. Value In Health. 2012; 15: 954–960.; Ипатова О. М., Медведева Н. В., Арчакова А. И., Григорьев А. И.; Трансляционная медицина — путь от фундаментальной био-; медицинской науки в здравоохранение. Вестник Российской; академии медицинских наук. 2012; 6: 57–65.; Van der Laan A. L., Boenink M. Beyond Bench and Bedside; Disentangling the Concept of Translational Research. Health Care; Anal. 2012. URL: http://link.springer.com; URL: http://www.inahta.net; Wagner P., Srivastava S. New paradigms in translational science; research in cancer biomarkers. Translational Research. 2012; 343–353.; Solans M., Guillamon I., Permanyer-Miralda G. et al. The impact; of Spanish research on mental health: An analysis of how knowledge; transfers into clinical practice through guidelines. Catalan Agency for; Health Information, Assessment and Quality. 2012; 3: 35–47.; Di Sabatino A., Moschetta A., Conte D. et al. The impact of; translational research on gastroenterology. Digestive and Liver; Disease. 2014; 46 (4): 293–294.; Sung N. S., Crowley W. F. Jr., Genel M. et al. Central challenges; facing the national clinical research enterprise. JAMA. 2003; 1278–1287.; Wehling M. Assessing the translatability of drug projects: what; needs to be scored to predict success? Nat Rev Drug Discov. 2009; 541–546.; Westfall J. M., Mold J., Fagnan L. Practice-based research —; «blue highways» on the NIH roadmap. JAMA. 2007; 297: 403–6.; Dougherty D., Conway P. H. The «3T’s» road map to transform; US health care: the «how» of high-quality care. JAMA. 2008; 2319–2321.; Drolet B., Lorenzi N. Translational research: understanding the conti-; nu um from bench to bedside. Translational Research. 2011; 1: 1–5.; Khoury M. J., Gwinn M., Yoon P. W. et al. The continuum of; translation research in genomic medicine: how can we accelerate; the appropriate integration of human genome discoveries into; health care and disease prevention? Genetics in Medicine. 2007; (10): 665–674.; Spoth R., Rohrbach L., Greenberg M. et al. Addressing Core; Challenges for the Next Generation of Type 2 Translation Research; and Systems: The Translation Science to Population Impact; (TSci Impact) Framework Springer. Prevention Science.; Р. 1–33.; Grimshaw J., Eccles M., Lavis J. et al. Knowledge translation; of research findings. Bio Med Central Implementation Science.; 7: 1–17.; Trochim W., Kane C., Graham M. J. et al. Evaluating translational; research: a process marker model. Clin Transl Sci. 2011; (3): 153–162.; Wang P ., Heinssen R., Oliveri M. et al. Bridging Bench and; Practice: Translational Research for Schizophrenia and Other; Psychotic Disorders. Neuropsychopharmacology. 2009; 204–212.; Lucas D., Kincl L., Bovbjerg V. et al. Application of a translational; research model to assess the progress of occupational safety; research in the international commercial fishing industry. Safety; Science. 2014; 64: 71–81.; Sarkar I., Butte A., Lussier Y. et al. Translational Bioinformatics; linking Knowledge across biological and clinical realms. J Am; Med Inform Assoc. 2011; 18: 354–357.; Cimino J., Ayres E., Remennik L. et al. The National Institutes; of Health’s Biomedical Translational Research Information System; (BTRIS): Design, contents, functionality and experience to date.; Journal of Biomedical Informatics. 2013. URL: http://www.j-biomed-; inform.com; Fishburn C. Translational research: the changing landscape of; drug discovery. Drug Discovery Today. 2012. Р. 1–8.; Butlet D. Translational Research: crossing the value of death.; Nature. 2008; 453: 840–842.; Millard W. NIH’s New NCATS: Bridging the Gulf From Bench to; Bedside. Annals of Emergency Medicine. 2011; 58 (20): 13–A17.; Evans S., Scarbrough H. Supporting knowledge translation; through collaborative translational research initiatives: «Bridging»; versus «blurring» boundary-spanning approaches in the UK; CLAHRS initiative. Social Science Medicine. 2014; 106: 119–127.; Шляхто Е. В. Трансляционная медицина: от науки к практике.; II Международный интернет-конгресс специалистов по внутренним болезням. 15.03.2013.; Стратегия развития медицинской науки до 2025 года.; Распоряжение Правительства Российской Федерации от 28 декабря 2012 г.; Российско-американский научный Форум по биомедицинским исследованиям. Отчет о 1-й ежегодной конференции.; Москва. 16–18 ноября 2011.; Fontana J., Alexander E., Salvatore M. Translational research; in infectious disease: current paradigms and challenges ahead.; Translational Research. 2012; 159 (6): 430–453.; https://www.pedpharma.ru/jour/article/view/91

الاتاحة: https://www.pedpharma.ru/jour/article/view/91
https://doi.org/10.15690/pf.v11i3.1002

المؤلفون: A. V. Pavlysh, A. S. Kolbin, R. A. Gapeshin, S. M. Malyshev, А. В. Павлыш, А. С. Колбин, Р. А. Гапешин, С. М. Малышев

المصدر: Pediatric pharmacology; Том 10, № 2 (2013); 19-23 ; Педиатрическая фармакология; Том 10, № 2 (2013); 19-23 ; 2500-3089 ; 1727-5776

مصطلحات موضوعية: оценка медицинских технологий, study design, health technology assessment, дизайн исследования

وصف الملف: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/230/539; https://www.pedpharma.ru/jour/article/view/230/340; Kleijnen S., Goettsch W., d’Andon A., Vitre P., George E., Goulden S., Osinska B., Rdzany R., Zawada A., Thirstrup S., Nagy B., Corbacho B. EUnetHTA JA WP5: Relative effectiveness assessment (REA) of pharmaceuticals. Background review. July, 2011 (version 5B).; Berger M. L., Dreyer N., Anderson F. et al. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012; 15 (2): 217–30.; Авксентьева М. В., Омельяновский В. В. Медицинские технологии. Оценка и выбор. 2001; 1: 52–58.; Kleijnen S., George E., Goulden S. et al. Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 yurisdiction. Value in Health. 2012; 15: 954–960.; High level pharmaceutical forum. Availability of data to conduct relative effectiveness assessments. Available at URL: http://ec.europa.eu/pharmaforum/effectiveness_en.htm (accessed December 2010).; Bown S. R. Scurvy: how a surgeon, a mariner, and a gentleman solved the greatest medical mystery of the age of sail. New York: St. Martin’s Press. 2003.; Federal coordinating council for comparative effectiveness research: report to the president and the congress. Washington, DC:US Department of Health and Human Services. June 30, 2009.; Sox H. C. Defining comparative effectiveness research: the importance of getting it right. Med Care. 2010; 48 (Suppl. 6): 7–8.; Tunis S. R., Benner J., McClellan M. Comparative effecti veness research: Policy context, methods development and research infrastructure. Stat Med. 2010; 29 (19): 1963–76.; Sox H., Goodman S. The methods of comparative effectiveness research. Annu Rev Public Health. 2012; 33: 425–450.; Hannan E. Randomized clinical trials and observational studies. Guidelines for assessing respective strengths and limitations. The American College of cardiology foundation. 2008; 1 (3): 211–7.; Клиническая эпидемиология. Основы доказательной медицины. Пер. с англ. под ред. Р. Флетчер, С. Флетчер, Э. Вагнер. М.: Медиа Сфера. 1998. 347 с.; Ren Y., Cacciato R., Whelehan M., Li N., Malmstrom H. S. Effects of toothbrushes with tapered and cross angled soft bristle design on dental plaque and gingival inflammation: a randomized and controlled clinical trial. Elsevier. Journal of Dentistry. 2007; 35: 614–622.; Klimt C. The conduct and principles of randomized clinical trials. Controlled Clinical Trials. 1981; 4: 283–293.; Evley R., Russell J., Mathew D. et al. Confirming the drugs administered during anaesthesia: a feasibility study in the pilot national health service sites, UK. Br J Anaesth. 2010; 105: 289–96.; Memtsoudis S., Besculides M. Perioperative comparative effectiveness research. Best Practice & Research Clinical Anaesthesiology. 2011; 4: 535–547.; Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987; 317: 141–5.; Skelly A. C., Dettori J. R., Brodt E. D. Assessing bias: the importance of considering confounding. Evid Based Spine Care J. 2012; 3 (1): 9–12.; Marko N. F., Weil R. J. The role of observational investigations in comparative effectiveness re-searches. Value Health. 2010; 13 (8): 989–97.; Didelez V., Meng S., Sheehan N. A. Assumptions of IV methods for observational epidemiology. Statist Sci. 2010; 25: 22–40.; Sorensen T. I. A. Which patients may be harmed by good treatments? Lancet. 1996; 348: 351–2.; Завидова С.С., Тополянская С.В., Намазова-Баранова Л.С. Клинические исследования лекарственных препаратов в педиатрии: проблемы и достижения. Педиатрическая фармакология. 2010; 7 (1): 6–14.; Kravitz R. L., Duan N., Braslow J. Evidence-based medicine, heterogenenity of treatment effects, and the trouble with averages. Milbank Q. 2004; 82: 661–87.; Heinze G., Juni P. An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011; 32 (14): 1704–8.; Gupta S. K. Intention-to-treat concept: a review. Perspect Clin Res. 2011; 2 (3): 109–12.; Busse R., Orvain J., Velasco M., Perleth M., Drummond M. et al. International Journal of Technology Assessment in Health Care. 2002; 18 (2): 361–422.; URL: http://www.inahta.net; URL: http://www.hta-rus.ru; URL: http://www.emaud.org; Tappenden P., Chilcott J., Ward S., Eggington S., Hind D., Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer. 2006; 42 (17): 2867–75.; https://www.pedpharma.ru/jour/article/view/230

الاتاحة: https://www.pedpharma.ru/jour/article/view/230
https://doi.org/10.15690/pf.v10i2.640